Smith-Magenis Syndrome insomnia
Neurology · 2021–2021
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| melatonin Treatment of insomnia in children aged 2–18 years with Smith-Magenis Syndrome (SMS) where sleep hygiene measures have been insufficient. | Nov 2021 | Recommended | input received National Aboriginal Community Controlled Health Organisation |
Who spoke
National Aboriginal Community Controlled Health Organisation
What the PBS pays
$0M in government benefit over 2024–25, across 2,592 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| melatonin | $0.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.